Evaluation of Patients' and Parents' Quality of Life in a Randomized Placebo-Controlled Atomoxetine Study in Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to demonstrate the superior efficacy of atomoxetine with respect to placebo and to compare parent and child perceptions of health-related quality of life (HRQoL). METHOD: This randomized, placebo-controlled, 12-week parallel clinical trial included 151 untreated children/adolescents with newly diagnosed attention-deficit/hyperactivity disorder (ADHD). Parents' and patients' reports of HRQoL were obtained separately using the Child Health and Illness Profile and compared using analysis of covariance. RESULTS: The ADHD Rating Scale baseline mean score was 39.21. Baseline HRQoL was perceived as considerably compromised by parents, especially in the risk avoidance and achievement domains (mean t-scores, 32.47 and 33.16, respectively), but less by children, and restricted to the achievement domain (mean t-score, 41.54). Atomoxetine improved HRQoL with respect to placebo in these two domains as assessed by parents (difference between adjusted mean changes and 95% confidence interval, 8.53, 4.05-13.00 and 3.39, 0.13-6.65) and in the risk avoidance domain by patients (3.56, 1.04-6.07). A modest correlation of clinical severity with HRQoL was found in this clinical population. CONCLUSIONS: This study confirms prior reports the impact of ADHD on the HRQoL of patients as assessed by their parents. The patients' perspective is of a lesser impact. Atomoxetine improved HRQoL as assessed by both parents and patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Klassen, A. F., Miller, A., & Fine, S. (2004) · Pediatrics · doi:10.1542/peds.2004-0844 · Cited by 565 · cited 2×
“…in the number of studies that have appeared over the last few years (Michelson et al. 2001; DeVeaugh-Geiss et al. 2002; Landgraf et al. 2002; Sawyer et al. 2002; Bastiaansen et al. 2004; Klassen et al. 2004; Matza et al. 2004; Perwien et al. 2004; Ralston and Lorenzo 2004; Escobar et al. 2005).”
Functional and psychosocial impairment in adults with undiagnosed ADHD
ABLE, S. L., JOHNSTON, J. A., ADLER, L. A., & SWINDLE, R. W. (2007) · Psychological Medicine · doi:10.1017/s0033291706008713 · Cited by 257 · cited 1×
“There are important implications of such an improvement, because HRQoL can be considered a general measure of functional impairment and associated emotional consequences (Sawyer et al. 2002; Barkley and Murphy 2005) that would lead to serious problems in adult-hood (Able et al. 2007).”
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185 · cited 2×
“The safety profile of atomoxetine was in line with prior reports (Cheng et al. 2007).”
MATZA, L. S., RENTZ, A. M., SECNIK, K., SWENSEN, A. R., REVICKI, D. A., MICHELSON, D., SPENCER, T., NEWCORN, J. H., & KRATOCHVIL, C. J. (2004) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200406000-00005 · Cited by 119 · cited 2×
“…in the number of studies that have appeared over the last few years (Michelson et al. 2001; DeVeaugh-Geiss et al. 2002; Landgraf et al. 2002; Sawyer et al. 2002; Bastiaansen et al. 2004; Klassen et al. 2004; Matza et al. 2004; Perwien et al. 2004; Ralston and Lorenzo 2004; Escobar et al. 2005).”
Prasad, S., Harpin, V., Poole, L., Zeitlin, H., Jamdar, S., Puvanendran, K., & on behalf of the SUNBEAM Study Group (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167309 · Cited by 97 · cited 3×
“Europe (ADORE) (Ralston and Lorenzo 2004) has shown particular improvement of parents’ perceptions of HRQoL with this drug compared to standard therapy (Prasad et al. 2007), but it had an open-label design and included both naı¨ve and treatment-experienced patients.”
Klimkeit, E., Graham, C., Lee, P., Morling, M., Russo, D., & Tonge, B. (2006) · Journal of Attention Disorders · doi:10.1177/1087054706289926 · Cited by 80
Cited by
Wehmeier, P. M., Schacht, A., & Barkley, R. A. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.09.009 · Cited by 628
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Jonsson, U., Alaie, I., Löfgren Wilteus, A., Zander, E., Marschik, P. B., Coghill, D., & Bölte, S. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12645 · Cited by 164
“In trials on pharmacological treatment for children with ADHD, however, the effect on QoL has recently been more regularly reported (e.g. Banaschewski et al., 2013; Escobar et al., 2009; Newcorn et al., 2008; Svanborg et al., 2009).”
Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
Metadata
- Authors
- Escobar, R., Montoya, A., Polavieja, P., Cardo, E., Artigas, J., Hervas, A., & Fuentes, J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-06
- Volume
- 19
- Issue
- 3
- Pages
- 253-263
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1978747908
- Cited by
- 48
- References
- 8
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.